Paclitaxel for Injection

DRUG4 trials

Sponsors

Bio-Thera Solutions, Suzhou Suncadia Biopharmaceuticals Co., Ltd., Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd.

Conditions

Cervical CancerMetastatic Pancreatic Ductal AdenocarcinomaPD-L1-positive Locally Recurrent Unresectable or Metastatic Triple-negative Breast CancerSolid Tumor

Phase 1

A Study of SHR-7367 With Anti-tumor Agents in Patients With Solid Tumors

RecruitingNCT07229586

Shanghai Hengrui Pharmaceutical Co., Ltd.Solid Tumor

Start: 2025-12-02End: 2027-12-31Target: 100Updated: 2025-12-19

Phase 2

BAT1308 Combined with Platinum-Based Chemotherapy± Bevacizumab for PDL1-Positive (CPS ≥1) Cervical Cancer

RecruitingNCT06123884

Bio-Thera SolutionsCervical Cancer

Start: 2023-12-13End: 2027-01-31Target: 526Updated: 2025-02-10

Phase 3

A Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast Cancer

RecruitingNCT07111832

Suzhou Suncadia Biopharmaceuticals Co., Ltd.PD-L1-positive Locally Recurrent Unresectable or Metastatic Triple-negative Breast Cancer

Start: 2025-08-20End: 2028-12-31Target: 400Updated: 2025-12-18

Clinical Trial Comparing TQB2868 Injection Combined With Anlotinib Hydrochloride Capsules With Placebo Combined With Chemotherapy as First-line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)

RecruitingNCT07165951

Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.Metastatic Pancreatic Ductal Adenocarcinoma

Start: 2025-12-02End: 2028-12-31Target: 566Updated: 2025-12-24

Related Papers

Primary efficacy and safety results of BAT1308, a PD-1 inhibitor, + chemotherapy ± bevacizumab in phase 2 trial for persistent, recurrent, or metastatic cervical cancer.

Journal of Clinical Oncology2025-05-28